Alaunos Therapeutics Inc
(STU:WEK)
€
1.66
0 (-4.82%)
Market Cap: 338.23 Mil
Enterprise Value: 276.94 Mil
PE Ratio: 0
PB Ratio: 1.04
GF Score: 54/100 ZIOPHARM Oncology Inc at Morgan Stanley Healthcare Conference Transcript
Sep 09, 2019 / 08:15PM GMT
Release Date Price:
€4.1
(-1.44%)
David Neil Lebowitz
Morgan Stanley, Research Division - VP
Welcome to the Morgan Stanley Healthcare Conference. And before I get going, I'm going to give the requisite disclosures. Please note that all important disclosures, including personal holdings disclosures and Morgan Stanley disclosures, appear on the Morgan Stanley public website at www.morganstanley.com/researchdisclosures or at the registration desk.
I'm one of the biotech analysts here. My name is David Lebowitz, and I'd like to -- I'm happy to welcome with me on the stage from ZIOPHARM, CEO, Dr. Laurence Cooper.
Laurence James Neil Cooper
ZIOPHARM Oncology, Inc. - CEO & Director
Thank you so much.
Questions & Answers
David Neil Lebowitz
Morgan Stanley, Research Division - VP
And I guess kind of a new company here in a way. If you could -- Ziopharm is a developer of immunotherapy for treatment -- immunotherapies for the treatment of cancer
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot